A peptide can bind a display molecule, be displayed by a cell, or be recognized by an immune receptor. These are different questions that require different evidence.
Binding prediction estimates one part of antigen selection. Immunopeptidomics examines peptides recovered with HLA molecules, while immune assays investigate receptor binding and functional responses. A primary melanoma study directly identified naturally presented mutated peptides and separately tested their immunogenicity. A consortium study likewise evaluated prediction against measured immune interactions. A candidate supported at one stage should retain that evidence level rather than being described as a demonstrated therapeutic target.
Shares Immunogenicity and clinical efficacy, Immune-cell cytotoxicity assays, Immune measurements and product evidence.
Shares Peptide-HLA multimer staining, Immune-cell cytotoxicity assays, Immune measurements and product evidence.
Shares Multi-epitope constructs and antigen processing, Immune measurements and product evidence.
Shares Multi-epitope constructs and antigen processing, Immune measurements and product evidence.
Shares Immunogenicity and clinical efficacy, Immune measurements and product evidence.
Shares Self-similarity and immune-recognition specificity, Immune measurements and product evidence.
Shares Immunopeptidomics, Immune measurements and product evidence.
Shares Immune-cell cytotoxicity assays, Immune measurements and product evidence.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/